Moreover, when monocyte-derived DCs from the same CAPS patients were evaluated 1 week after anti-IL-1β treatment, a clear reduction of the secretion of both IL-1β and IL-23 was found, as already observed for IL-1β in NLRP3-mutated monocytes after in vivo treatment with IL-1 blockers [17]. This evidence concerns the gene IL1B and cryopyrin-associated periodic syndrome.